MedTrace Logo

Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma

NCT05139134 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-07-29

No results posted yet for this study

Summary

Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis. CXCL5 have been implicated in progression of many cancers, but their significance in urinary bladder UC remains unclear.

Conditions

  • Urinary Bladder Urothelial Carcinoma

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Nagwa Ahmed, Lecturer · Sohag University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-05-01
Completion
2022-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05139134 on ClinicalTrials.gov